Prevalence and Safety of Prescribing PPIs with Clopidogrel in Palestine

Figures & data

Figure 1 Study Flow Chart.

Table 1 The Characteristics of the Sample (N= 443)

Variable	Category	n (%)
Gender	Female	84 (19.0)
	Male	359 (81.0)
Age	40 or less	41 (9.3)
	41–50	100 (22.6)
	51–60	156 (35.2)
	61–70	124 (28.0)
	70 or more	22 (5.0)
Comorbidities	Hyperlipidemia	239 (54)
	Hypertension	211 (47.6)
	Diabetes Mellitus	187 (42.2)
	COPD	34 (7.7%)
	Chronic Kidney Disease	32 (7.2)
	Peptic Ulcer Disease	18 (4.1)
	Liver Disease	40 (0.9)
	Dementia	9 (0.2)
CCI score	0	199 (44.9)
	1	157 (35.4)
	2	55 (12.4)
	3 or more	32 (7.2)
Anti-acid use	None	102 (23.0)
	On PPI	331 (74.7)
	Taking H2RA	10 (2.3)
Taking DAT (dual antiplatelet therapy)	Yes	413 (93.2)
Cardiovascular event	Yes	59 (13.3)

Table 2 Association Between CV Events and Other Variables. (N=443)

Variable	Category	Cardiovascular Event		P-value
		Yes n (%)	No n (%)
Gender	Male	44 (12.3%)	315 (87.7%)	0.174
	Female	15 (17.9%)	69 (82.1%)
Age	40 or less	6(14.6%)	35(85.4%)	0.989
	41–50	13 (13.0%)	87 (87.0%)
	51–60	22 (14.1%)	134 (85.9%)
	61–70	15 (12.1%)	109 (87.9%)
	71 or more	3 (13.6%)	19 (86.4%)
CCI score	None	22 (11.1%)	177 (88.9%)	Ref.
	1	14 (8.9%)	143 (91.1%)	0.507
	2	12 (21.8%)	43 (78.2%)	0.042
	3 or more	11 (34.4%)	21 (65.6%)	0.001
On PPI	Yes	45 (13.6%)	286 (86.4%)	0.768
	No	14 (12.5)	98 (87.5)
On statin therapy	Yes	24 (10.0%)	215 (90.0%)	0.028
	No	35 (17.2%)	169 (82.8%)
Hypertension	Yes	31 (14.7%)	180 (85.3%)	0.417
	No	28 (12.1%)	204 (87.9%)

Table 3 Association Between PPI Molecules and CV Events. (N=331)

PPI Name	PPI Total n(%)	Cardiovascular Event		P-value
		Yes n(%)	No n(%)
Pantoprazole	113 (34.1%)	18 (15.9%)	95 (84.1%)	0.408
Omeprazole	11 (3.3%)	2 (18.2%)	9 (81.8%)
Lansoprazole	9 (2.7%)	2 (22.2%)	7 (77.8%)
Esomeprazole	198 (59.8)	23 (11.6%)	175 (88.4%)

Table 4 Association Between CV Events Comparing Interacting PPIs to Non-Interacting (N=443)

Variable		Cardiovascular Event n (%)		P-value
		Yes	No
Anti-acid	None, Pantoprazole, or H2RA	32 (14.2)	193 (85.8)	0.579
	Omeprazole, esomeprazole or lansoprazole	27 (12.4)	191 (87.6)

Figure 2 The median time to CV Events.